Microcap Cognition Therapeutics (NASDAQ:CGTX) has skyrocketed 35% in Thursday trading after stating the company had a ...

Japanese authorities are putting Eisai (TYO: 4523) under pressure to reconsider the price of its Alzheimer’s disease therapy ...

The FDA will allow a new dosing schedule for Eli Lilly’s Alzheimer’s drug Kisunla that could lessen a known side effect of ...

Biogen shares slipped on Monday after the company said it expects to take a $46 million charge in the second quarter related ...

A slower ramp-up of Kisunla dosing lowers the rate of dangerous brain swelling, a risk that has made doctors reluctant to ...

Chris Long and his wife, Janet, were thrilled when he became the first patient at MUSC Health to receive the Alzheimer’s drug ...

Learn about interactions between Leqembi and other medications, supplements, alcohol, and more. You can also find out when to avoid Leqembi.

Tony Downs is one of the first patients in the country to take Leqembi, a newly approved drug. He and his wife are hoping it will help slow his downhill path.

Learn about side effects, uses, cost, and more for Leqembi (lecanemab-irmb), a prescription drug that treats Alzheimer’s disease in adults.

Leqembi — sold through a partnership between Eisai Co. and Cambridge-based Biogen — is one of the first medications approved that promises to slow the speed at which Alzheimer’s erases a ...

Leqembi, an Alzheimer's drug from Biogen and Eisai, could give patients at the earliest stages of the disease more time to live normally and independent of others. But patients face a long road to ...

Leqembi selectively binds to soluble amyloid-beta (Aβ) aggregates (protofibrils2), as well as insoluble Aβ aggregates (fibrils) which are a major component of Aβ plaques in Alzheimer's disease ...